Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know:

Get the latest public health information from CDC:

Get the latest research information from NIH:

Principal Investigator
Ed Partridge
University of Alabama at Birmingham
About this CDAS Project
PLCO (Learn more about this study)
Project ID
Initial CDAS Request Approval
Jul 1, 2006
Prediction of Ovarian Neoplasm by TVU Morphology Results and CA 125 Levels
To determine the risk of malignancy in the 1604 women found to have abnormal CA125 and/or transvaginal ultrasound
(TVU) at the initial screen and the 1566 women found to have an abnormal result at subsequent screens among the
39,115 women receiving both tests and having ovaries present in the intervention arm of the Prostate, Lung, Colorectal,
and Ovarian (PLCO) Cancer Screening Trial.

In this large trial, a positive screen was defined as CA125 > 35 U/ml; ovarian or cyst volume > 10cm3; or, solid areas,
papillary projections, or mixed components within a cystic ovarian tumor of any size. We attempted to determine further
criteria for establishing risk of malignancy in asymptomatic postmenopausal women following an abnormal screen, and
calculated sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of the